Parkinson's disease (PD) is a chronic neurodegenerative condition which has the second largest incidence rate among all other neurodegenerative disorders barring Alzheimer's disease (AD). Currently there is no cure and researchers continue to probe the therapeutic prospect in cell cultures and animal models of PD. Out of the several factors contributing to PD prognosis, the role of p38 MAPK (Mitogen activated protein-kinase) and PI3K/AKT signalling module in PD brains is crucial because the impaired balance between the pro-apoptotic and anti-apoptotic pathways trigger unwanted phenotypes such as microglia activation, neuroinflammation, oxidative stress and apoptosis. These factors continue challenging the brain homeostasis in initial stages thereby essentially assisting the dopaminergic (DA) neurons towards progressive degeneration in PD. Neurotherapeutics against PD shall then be targeted against the misregulated accomplices of the p38 and PI3K/AKT cascades. In this review, we have outlined many such established mechanisms involving the p38 MAPK and PI3K/AKT pathways which can offer therapeutic windows for the rectification of aberrant DA neuronal dynamics in PD brains.
but are not equipped enough to annul the effects or for that reason heal the infirm. Sadly though, the future of such ambitious modalities currently hangs on morbid conjecture and fragile hopes and thus the current focus of the research bevy is to primarily delve unprecedented mechanisms that shall in future restrain the cardinal effects in NDs and also presumably act as custodians of permanent cure (4, 5) .
PD is a chronic, neurodegenerative state and the second most commonly observed brain disorder (the most common being AD) which impacts nearly 1% of the global population aged 65 and older.
Incidentally, PD appears to be less prevalent among Asian population as compared to the Western world and it is unclear whether this is in a way allied to the extensive use of traditional medicine in the Eastern half of the planet (6) . Nevertheless, the use of complementary and alternative medicine (CAM) has been reported to be as high as 76% in countries like Korea. PD is typically characterized by the progressive loss of muscle control, impaired balance, slowness, akinesia, bradykinesia, tremors, postural instability, and decline in striatal dopamine levels of the central nervous system (CNS), and rigidity observed due to the significant loss of dopaminergic (DA) neurons in the substantia nigra (SN) in the midbrain (7) . Interestingly, only 10% of all PD cases are caused by genetic mutations, and animal models previously used to comprehend these mutations revealed a significant insight into the loss-of-function status of α-synuclein and will offer this modality typically to infirm with disruptive motor complications obstinate to drug treatment (13, 14) . Therefore, it is of urgency to examine novel mechanisms that can be used as a 
PI3K/AKT/mTOR pathway
The PI3K-PKB/ Akt pathway is highly AKT is a serine/ threonine kinase which is expressed as three isoforms, AKT1, AKT2 and AKT3, which are encoded by three PKB genes namely α (PKBα), β (PKBβ), and γ (PKBγ). All the three isoforms can be characterized based upon a parallel architecture comprising of an N-terminal PH domain, a central serine/threonine catalytic domain, and a small C-terminal regulatory domain.
Initial AKT activation is facilitated by translocation to the plasma membrane mediated by docking of the PH domain to the membranous phospholipid PI(3,4,5)P 3 , resulting a change in AKT conformational and subsequently divulging the two critical amino acid residues for phosphorylation.
Phosphorylation at both the exposed sites, T308 by PDK1 and S473 by PDK2, are a prerequisite in order for the AKT to achieve full activation status.
Once AKT is activated by phosphorylation at T308
and S473, it then facilitates the phosphorylation of 
